Qiao Xin-Min, Wang Zhong-Min
Dalian Obstetric and Gynecologic Hospital, Dalian,Liaoning, 116033, P.R.China.
Ai Zheng. 2004 Jan;23(1):81-4.
BACKGROUND & OBJECTIVE: It was reported that vascular cell adhesion molecule-1 (VCAM-1) was highly expressed in ovarian carcinoma samples. The latest research showed that the concentration of serum soluble VCAM-1 (sVCAM-1) was increased in the patients with various tumors. The aim of this study was to investigate the biological effects of sVCAM-1 on epithelial ovarian carcinoma.
The concentration of serum sVCAM-1 was assayed in 130 normal cases, 50 benign ovarian tumors, and 67 epithelial ovarian carcinoma cases using enzyme-linked immunoadsorbent assay(ELISA).
The serum sVCAM-1 level in epithelial ovarian carcinoma[(897+/-54) g/L,83.6%] was higher than those in benign ovarian tumor [(435+/-43) g/L, 8.0%] and normal cases [(420+/-40) microg/L,6.2%] (P< 0.01), while the former dropped post-operation [(532+/-46) microg/L,37.3%]. The serum sVCAM-1 levels in stage II-IV [(899+/-71) microg/L,93.3%], grade III [(982+/-66) microg/L,94.8%], and the cases combined with lymphatic metastasis [(895+/-58) microg/L,95.1%] were higher than those in stage I[(571+/-49) microg/L,63.6%], grade I [(641+/-51)microg/L,69.2%], grade II[(768+/-47)microg/L,66.7%], and the cases without lymphatic metastasis[(728+/-47) microg/L,65.4%](P< 0.05, P< 0.01, and P< 0.01, respectively); while no correlation was found between serum sVCAM-1 levels and histological types (P >0.5). No correlation was found between concentration of sVCAM-1 and prognosis by multiple factor analysis.
Dynamically monitoring the concentration of serum sVCAM-1 will hopefully become an index for early diagnosis and supervising the recurrence of epithelial ovarian carcinoma.
据报道，血管细胞黏附分子-1（VCAM-1）在卵巢癌样本中高表达。最新研究表明，多种肿瘤患者血清可溶性VCAM-1（sVCAM-1）浓度升高。本研究旨在探讨sVCAM-1对上皮性卵巢癌的生物学作用。
采用酶联免疫吸附测定法（ELISA）检测130例正常对照、50例良性卵巢肿瘤及67例上皮性卵巢癌患者血清sVCAM-1浓度。
上皮性卵巢癌患者血清sVCAM-1水平[（897±54）μg/L，83.6%]高于良性卵巢肿瘤患者[（435±43）μg/L，8.0%]和正常对照[（420±40）μg/L，6.2%]（P<0.01），术后该水平下降[（532±46）μg/L，37.3%]。Ⅱ-Ⅳ期[（899±71）μg/L，93.3%]、Ⅲ级[（982±66）μg/L，94.8%]及合并淋巴结转移患者[（895±58）μg/L，95.1%]血清sVCAM-1水平高于Ⅰ期[（571±49）μg/L，63.6%]、Ⅰ级[（641±51）μg/L，69.2%]、Ⅱ级[（768±47）μg/L，66.7%]及无淋巴结转移患者[（728±47）μg/L，65.4%]（分别为P<0.05、P<0.01和P<0.01）；血清sVCAM-1水平与组织学类型无关（P>0.5）。多因素分析显示sVCAM-1浓度与预后无关。
动态监测血清sVCAM-1浓度有望成为上皮性卵巢癌早期诊断及复发监测的指标。
